Abstract
The interactions between disease processes and the metabolism of therapeutic drugs have not been systematically investigated. Inflammation, with the presence of pro-inflammatory cytokines, affects Phase 1 metabolism, particularly the activity of the CYP isoforms. Inflammatory factors also alter the activity of some Phase 2 enzymes, particularly the sulphotransferases (SULT isoforms) responsible for drug sulphonation and the enzyme pathway involved in the supply of sulphate for this reaction. Being ill may, therefore, in itself make drug metabolism unpredictable.
Keywords: Inflammation, Illness, Sulphation, Drug Metabolism, Xenobiotic, Drug Reactions, SULT, Isoforms, Phase 2, Cytokines, Sulphate
Current Drug Metabolism
Title:Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Volume: 14 Issue: 3
Author(s): R.H. Waring, R.M. Harris, J.O. Hunter and S.C. Mitchell
Affiliation:
Keywords: Inflammation, Illness, Sulphation, Drug Metabolism, Xenobiotic, Drug Reactions, SULT, Isoforms, Phase 2, Cytokines, Sulphate
Abstract: The interactions between disease processes and the metabolism of therapeutic drugs have not been systematically investigated. Inflammation, with the presence of pro-inflammatory cytokines, affects Phase 1 metabolism, particularly the activity of the CYP isoforms. Inflammatory factors also alter the activity of some Phase 2 enzymes, particularly the sulphotransferases (SULT isoforms) responsible for drug sulphonation and the enzyme pathway involved in the supply of sulphate for this reaction. Being ill may, therefore, in itself make drug metabolism unpredictable.
Export Options
About this article
Cite this article as:
Waring R.H., Harris R.M., Hunter J.O. and Mitchell S.C., Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?, Current Drug Metabolism 2013; 14 (3) . https://dx.doi.org/10.2174/1389200211314030011
DOI https://dx.doi.org/10.2174/1389200211314030011 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Multitarget-Directed Ligands: Innovative Chemical Probes and Therapeutic Tools Against Alzheimer's Disease
Current Topics in Medicinal Chemistry Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Dysregulated Pathway Identification of Alzheimer's Disease Based on Internal Correlation Analysis of Genes and Pathways
Combinatorial Chemistry & High Throughput Screening Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Recent Progress in Biomedical Applications of Magnetic Nanoparticles
Recent Patents on Nanotechnology Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine